Blog

Welcome to CrownBio’s Blog where we share our thoughts
on the latest trends and hot stories in Cvmd

blog.png
June 19, 2018 DGAT2 Inhibition Doesn’t Affect Plasma Triglycerides, VLDL ApoB In a new study published in Cell Metabolism, McClaren et al utilize a variety of translational models, including both mouse models and non-human primate (NHP) models of obesity, to explore a potential therapeutic target for dyslipidemia. Their study focused on the effects of DGAT2 inhibition on lipid metabolism and whole-body metabolic flux. LEARN MORE
June 7, 2018 Is an Approved NASH Therapy on the Way? Non-alcoholic steatohepatitis (NASH) is an unmet medical need with no approved therapies and debilitating consequences ... LEARN MORE
March 22, 2018 Are There Are Five Types of Diabetes? New research suggests that there are five types of diabetes, rather than simply Type 1 or Type 2. Understanding ... LEARN MORE
March 7, 2018 New Technique Opens Novel Approaches to Insulin Resistance A newly-described technique could open multiple lines of investigation into the pathophysiology and treatment of ... LEARN MORE
October 10, 2017 ADA 2017 Video Poster Review Naturally Diabetic NHP Immune Cell Changes Correspond to Human Type 2 Diabetes While changes in immune cell ... LEARN MORE
September 28, 2017 Impact of Anesthesia During Comprehensive Assessments On Glucose Homeostasis in Diabetic NHPs In the clinic, either an oral glucose (oGTT) or mixed meal (MMTT) tolerance test is used to provide comprehensive ... LEARN MORE
September 14, 2017 First Type 2 Diabetes Publication Comparing Pros and Cons of Two Preclinical Continuous Glucose Monitoring Systems Significant Correlation between Blood Glucose Levels Measured by Glucometer and both the Dexcom G4 Platinum and HD-XG Telemetry Device from Wang et al. Sci Rep 2017;7(1):9596. LEARN MORE
August 31, 2017 Recent Type 2 Diabetes Publication Demonstrates Preclinical Study Benefits of Continuous Glucose Monitoring Daily Blood Glucose Fluctuations in Normal and Diabetic NHPs from Wang et al. J Endocrinol Invest 2017;40(9): 967-977. ... LEARN MORE
August 17, 2017 How to Optimize your Non GLP Toxicology Studies Most new drug candidates fail in the clinic because they are not efficacious or are not safe. Optimizing non-clinical ... LEARN MORE
August 1, 2017 NASH Drug Development Race Intensifies There is no FDA-approved treatment for NASH, which affects 3-5% of Americans. Competition to deliver the first ... LEARN MORE
July 27, 2017 Polycystic Kidney Disease (PKD): The Argument for Multiple Rodent Models Rodent models of PKD are critical to studying both its molecular basis and progression, but the complexity of Polycystic kidney disease's cellular alterations and signaling pathways make the leap from preclinical studies to approved treatment of human disease almost impossible. The use of multiple animal models in parallel may be the most effective ... LEARN MORE
July 13, 2017 Progress Towards a Cure for Polycystic Kidney Disease Polycystic kidney disease (polycystic kidney syndrome, PKD, or PCKD) is a genetic disorder in which numerous abdominal ... LEARN MORE
June 15, 2017 Why the Current Excitement over Krill in CVD? Krill are small crustaceans found in all the world's oceans, which have been harvested as a human and animal food ... LEARN MORE
June 6, 2017 PCSK9 Inhibitor Data in Diabetic Patients to be Highlighted at ADA 2017 Recent years have witnessed a change in cholesterol-lowering compounds - from your parents’ standard statin treatment ... LEARN MORE
May 18, 2017 Can We Develop Translational Platforms that Model Multiple Aspects of Human Diabetes? A significant challenge in the development of new anti-diabetic therapies is the lack of translational platforms that ... LEARN MORE